We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





People with Absence of Natural Killer Cell Receptor Most Likely to Develop Severe COVID-19, Finds Study

By HospiMedica International staff writers
Posted on 23 Feb 2021
People with a partial or total absence of a special, activating receptor in natural killer cells (NK cells) that destroy virus-infected cells are most likely to develop severe COVID-19.

A research group from the Center for Virology at the Medical University of Vienna (Vienna, Austria) has shown that that people who required hospitalization with COVID-19 were significantly more likely to exhibit a genetic variation due to which approximately 4% of the population naturally lack the activation receptor NKG2C, and in 30% of the population this receptor is only partially available.

Normally, the antiviral immune response of NK cells is an important step in combating viral replication in the early phase of the infection. More...
On their surface, these killer cells have special, activating receptors, including the NKG2C receptor, which communicates with an infected cell via one of its specialized surface structures, HLA-E. This interaction results in the destruction of virus-infected cells. The researchers have shown that people who required hospitalization with COVID-19 were significantly more likely to exhibit the genetic variation underlying the lack of the receptor than people who only experienced mild disease. The study indicates the major importance of NK-cell response in the battle against SARS-CoV-2 infection.

"Absence of the receptor was particularly prevalent in COVID-19 patients being treated in intensive care units, irrespective of age or gender. Genetic variations on the HLA-E of the infected cell were also associated with disease severity, albeit to a lesser extent," said Elisabeth Puchhammer-Stöckl who led the research team. "This part of the immune response could therefore also represent an important target for drugs that could help to prevent severe COVID-19 disease."

Related Links:
Medical University of Vienna


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.